Stress urinary incontinence is a condition characterized by involuntary leakage of urine during physical activity or stress. The disorder affects around 10-20% of the population, predominantly affecting women. There is a high unmet clinical need for better therapies, as current treatment options, such as pelvic floor exercises, medications, and surgical interventions, often fail to deliver lasting results. Furthermore, the growing focus on innovative drug development and minimally invasive treatments is likely to support pipeline growth in the coming years, providing hope for more effective and long-term management solutions for stress urinary incontinence.
The Stress Urinary Incontinence Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into stress urinary incontinence therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for stress urinary incontinence. The stress urinary incontinence report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The stress urinary incontinence pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with stress urinary incontinence treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to stress urinary incontinence.
Stress urinary incontinence is the involuntary leakage of urine due to physical stress, such as coughing, sneezing, or exercising. It occurs when the pelvic floor muscles and bladder sphincter weaken, impairing their ability to retain urine during physical activity. This condition primarily affects women, especially after childbirth or menopause.
Stress urinary incontinence treatments include behavioral therapies, medications, and surgical options. Conservative treatments like pelvic floor exercises strengthen muscles, while medications manage symptoms. In severe cases, surgical interventions such as slings or bladder neck suspension may provide long-term relief. Emerging drug therapies are being developed to address underlying causes.
A 2023 report indicates that stress urinary incontinence (SUI) is globally prevalent, with prevalence rates increasing across various regions. In the United States, up to 60% of women in certain communities are affected. The condition significantly impacts quality of life, leading to physical, social, psychological, and financial challenges. In the Middle East, prevalence rates range from 20.3% to 54.8%.
This section of the report covers the analysis of stress urinary incontinence drug candidates based on several segmentations, including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II holds a significant share of the total stress urinary incontinence clinical trials.
The drug molecule categories covered under the stress urinary incontinence pipeline analysis include small molecules, monoclonal antibodies, and peptides. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for stress urinary incontinence.
The EMR stress urinary incontinence drug report insights include the profiles of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in stress urinary incontinence clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for stress urinary incontinence. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of stress urinary incontinence drug candidates.
The "CELLEBRATE" Phase 3 clinical trial, sponsored by Cook MyoSite, evaluates the efficacy and safety of Autologous Muscle Derived Cells (AMDC-USR) for urinary sphincter repair compared to a placebo in adult women with post-surgical stress urinary incontinence. The study aims to assess the reduction in incontinence episodes. The study is expected to be completed by February 2026 and involves around 96 participants.
The Phase 2a study, sponsored by Versameb AG, aims to evaluate the safety, tolerability, and efficacy of VMB-100 in females with moderate stress urinary incontinence. VMB-100, an mRNA encoding IGF-1, is injected into the urethral sphincter to promote muscle regeneration. The study, expected to conclude by November 2028, will involve 30 participants and focus on improving sphincter function to alleviate incontinence.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Stress Urinary Incontinence Drug Pipeline Insight Report offers a strategic overview of the latest and future landscape of treatments for stress urinary incontinence. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within stress urinary incontinence pipeline insights.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share